(4-异丙氧基苯基)-肼 | 736891-34-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-异丙氧基苯基)-肼
• 英文名称: (4-isopropoxy-phenyl)-hydrazine
• 英文别名: (4-propan-2-yloxyphenyl)hydrazine
• CAS: 736891-34-2
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: BKOQVJSQNRRGBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-异丙氧基苯基)-肼 在 sodium hydride 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 6.0h， 生成 5-Chloro-4-(4-methoxyphenoxy)-2-(4-propan-2-yloxyphenyl)pyridazin-3-one
  参考文献：
  名称：

  Design, synthesis and SAR analysis of novel potent and selective small molecule antagonists of NPBWR1 (GPR7)

  摘要：

  Novel smallmolecule antagonists ofNPBWR1 (GPR7) are herein reported. A high-throughput screening (HTS) of the Molecular Libraries-Small Molecule Repository library identified 5-chloro-4-(4-methoxyphenoxy)-2-(p-tolyl)pyridazin-3(2H)-one as a NPBWR1 hit antagonist with micromolar activity. Design, synthesis and structure-activity relationships study of the HTS-derived hit led to the identification of 5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy) pyridazin-3(2H)-one lead molecule with sub-micromolar antagonist activity at the target receptor and high selectivity against a panel of therapeutically relevant off-target proteins. This lead molecule may provide a pharmacological tool to clarify the molecular basis of the in vivo physiological function and therapeutic utility of NPBWR1 in diverse disease areas including inflammatory pain and eating disorders. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.074

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015086636A1

  公开（公告）日：2015-06-18

  This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

  该应用程序根据通用公式（I）披露化合物：其中所有变量的定义如本文所述，这些化合物抑制Btk。本文披露的化合物对调节Btk的活性并治疗与过度Btk活性相关的疾病有用。这些化合物对于治疗由异常B细胞活化引起的肿瘤学、自身免疫和炎症性疾病是有用的。还披露了含有公式I化合物和至少一种载体、稀释剂或赋形剂的组合物。
• ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20140315961A1

  公开（公告）日：2014-10-23

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

  本文描述了式（I）的化合物，其药学上可接受的盐以及药物组成物。本发明的化合物对抑制精氨酸甲基转移酶活性是有用的。还描述了利用这些化合物治疗精氨酸甲基转移酶介导的疾病的方法。
• 光催化条件下合成砜类化合物的方法
  申请人：河南大学

  公开号：CN112574077B

  公开（公告）日：2022-02-22

  本发明属于化合物制备技术领域，具体涉及一种光催化条件下合成砜类化合物的方法。以芳肼和亚磺酸盐为原料，在碱和溶剂作用下，经可见光光照，在空气或者氧气条件下反应生成砜类化合物。本发明方法以芳肼作为芳基化试剂，以多酸盐为催化剂或者有机光敏剂为催化剂，在室温条件下经可见光照射，便可实现与亚磺酸盐偶联高效合成砜类化合物。该方法具有较好的底物普适性和相对温和的反应条件，不仅是目前报道从简单底物出发经偶联合成砜类化合物的一种替代，而且还拓宽了多酸盐在光催化领域的新应用。
• NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：Shionogi & Co., Ltd.

  公开号：EP2604260A1

  公开（公告）日：2013-06-19

  The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; -X- is -N(R16)- or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is -O-, -S- or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了具有 P2X3 和/或 P2X2/3 受体拮抗作用的新型化合物。 一种具有 P2X3 和/或 P2X2/3 受体拮抗作用的药物组合物，由式（I）化合物组成： 其中 环 A 是取代或未取代的 5 至 7 元环烷烃、取代或未取代的 5 至 7 元环烯烃或类似物； C 是碳原子； -X-是-N(R16)-或类似物； R16 是氢、取代或未取代的烷基或类似物； R7 是取代或未取代的 5 或 6 元杂芳基、取代或未取代的 6 至 10 元芳基； Q1和Q2各自独立地为碳原子或氮原子； -L-是-O-、-S-或类似物； R6 是取代或未取代的环烷基、取代或未取代的环烯基或类似物； R2 是氢、羟基或类似物、 或其药学上可接受的盐或其溶液。
• Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain
  作者：James W. Myatt、Mark P. Healy、Gianpaolo S. Bravi、Andrew Billinton、Christopher N. Johnson、Kim L. Matthews、Karamjit S. Jandu、Wenjing Meng、Anne Hersey、David G. Livermore、Clement B. Douault、Jason Witherington、Rino A. Bit、James E. Rowedder、Jason D. Brown、Nick M. Clayton

  DOI：10.1016/j.bmcl.2010.05.026

  日期：2010.8

  Optimization of the novel alpha-2-delta-1 ligand 4 provided compounds 37 and 38 which have improved DMPK profiles, good in vivo analgesic activity and in vitro selectivity over alpha-2-delta-2. An in-house P-gp prediction programme and the MetaSite (R) software package were used to help solve the specific problems of high P-gp efflux and high in vivo clearance. (C) 2010 Elsevier Ltd. All rights reserved.